Centiva Capital’s Novavax NVAX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-43,400
Closed -$791K 1551
2022
Q3
$791K Sell
43,400
-10,000
-19% -$433K 0.01% 718
2022
Q2
$2.75M Sell
53,400
-3,500
-6% -$181K 0.07% 270
2022
Q1
$4.19M Sell
56,900
-1,000
-2% -$89.2K 0.08% 212
2021
Q4
$8.28M Buy
57,900
+54,900
+1,830% +$9.43M 0.17% 110
2021
Q3
$623K Sell
3,000
-16,300
-84% -$3.59M 0.04% 547
2021
Q2
$4.1M Buy
+19,300
New +$3.54M 0.1% 166

Other funds holding NVAX

Centiva Capital's NVAX Position: Q1 2025 in Review

Centiva Capital sold out of Novavax (NVAX) in Q1 2025, closing a stake of 11,959 shares — an estimated $96.2K sold.

Centiva Capital first reported a position in NVAX in Q1 2021 and held it in 9 quarters. The position peaked at $3.72M in Q4 2021. 246 funds tracked by Wall St. Rank hold NVAX as of Q1 2025.

  • Centiva Capital reported no remaining Novavax position as of Q1 2025 after selling out during the quarter.
  • Centiva Capital sold 11,959 Novavax shares in Q1 2025, an estimated $96.2K.
  • Centiva Capital first reported a position in Novavax in Q1 2021 and held it in 9 quarters.
  • Centiva Capital's Novavax position peaked at $3.72M in Q4 2021.
  • 246 funds tracked by Wall St. Rank held Novavax as of Q1 2025.

Based on Centiva Capital's 13F filing for Q1 2025, filed 15 May 2025.